Skip to main content
Premium Trial:

Request an Annual Quote

Ulf Jonsson New CEO of Cellectricon, Invitrogen and Bruker Hire New CFO s, Emily Winn-Deen Joins Cepheid as VP Strategic Planning, Three Share Chemistry Nobel for Protein Breakdown Studies, and Others

Ulf Jonsson has been appointed as chief executive officer of Cellectricon, effective Jan. 1, 2005, the company said last week. Jonsson will be replacing Jakob Lindberg, one of the company's co-founders, who recently announced his planned resignation. He previously served as CEO of Biacore. Jonsson holds a PhD in applied physics.


William Knight has become CFO of Bruker Biosciences, the Billerica, Mass.-based company said yesterday. He will start his appointment on Oct. 25. Knight joins Bruker from Anika Therapeutics of Woburn, Mass., where he was also CFO. He holds a bachelor's degree in business administration from the Universityof Wisconsin.


David Hoffmeister has become CFO and senior vice president of Invitrogen, succeeding Eric Winzer, the Carlsbad, Calif.-based company said yesterday. He joins the company from McKinsey, where he was a senior partner. Winzer will remain part of the Invitrogen executive team.


Kate Gilbert has been promoted to director of marketing of Ciphergen Biosystems. She replaces Dick Rubin, who left the company in August. Gilbert was previously consumables product manager at Ciphergen.


Emily Winn-Deen has joined Cepheid of Sunnyvale, Calif., as vice president of strategic planning and business development, the company said last month. Most recently, she led the genomics business group at Roche Molecular Systems in Pleasanton, Calif.In the past, she held appointments at Applied Biosystems, Oncor, and Celera Genomics. Winn-Deen holds a PhD in chemistry from BostonUniversity and a BS in chemistry from LehighUniversity.


Sam Rua has become director of regulatory affairs and quality assurance of Third Wave Technologies, the Madison, Wis.-based company said yesterday. Rua, 44, joins the company from Ventana Medical Systems, where he was director of regulatory affairs. He holds a bachelor's degree in microbiology from the Universityof Arizona.


Jennifer Joiner has become vice president for the Companion Animal Group North American Operations of Idexx Laboratories, the Westbrook, Maine-based company said last week. She comes to Idexx from Molecular Staging, where she was responsible for developing the business plan, creating a commercial operations team, and executing a launch for a range of genomics products and services. Joiner holds a BEc in economics from LaTrobeUniversity in Australia.


Laurie Keatinghas become senior vice president, general counsel, and secretary of Millennium Pharmaceuticals, the Cambridge, Mass.-based company said last week. Most recently, she was executive vice president of operations and finance and a member of the board of directors of Hydra Biosciences.


Gary Fagan has been promoted to vice president for research and development at Matritech, the Newton, Mass.-based company said last week. He used to be senior director for product development and was appointed as acting CSO this summer. Fagan holds a PhD in microbiology and immunology from the University of California at San Francisco and a BA in zoology from the Universityof New Hampshire.


Biotage has promoted a number of employees within its Biosystems group: Katherine Webster, previously VP of worldwide sales, has become president of the group; Rene Myers has been promoted to vice president of technology support, from director of science and technology; Maria Hjortsmark, previously product manager, is now vice president of development; Robert England has been promoted to director of global marketing communications, from corporate marketing communications director; and Viveca Johansson, who used to be supply manager, has become vice president of supply.


Paul Schimmel and Christoph Westphal, among others, have joined the newly-formed board of directors of Sirtris Pharmaceuticals, the company said earlier this month. Schimmel is a faculty member of the Scripps Institute and a cofounder of Alnylam Pharmaceuticals. He holds a PhD from the Massachusetts Institute of Technology. Westphal is a general partner at the venture capital firm Polaris Venture Partners and CEO of Sirtris. He is also a co-founder, and was the startup CEO, of Alnylam. Westphal holds a PhD and MD from Harvard Medical School.


Michael Khoury and Joseph Wender have been appointed to the board of directors of Neurome, the La Jolla, Calif.-based company said last week. Wenders is an advisory director and senior director of the Financial Institutions group at Goldman Sachs. He received an MBA fro Harvard Business School, an LLB from Yale Law School, and a bachelor's degree from NorthwesternUniversity. Khoury is a financial advisor and independent consultant. He holds an MBA from the University of California Los Angeles, an MFA from New YorkUniversity, and a BS in mathemantics from the American University of Beirut.


Aaron Ciechanover, Avram Hershko, and Irwin Rose have won this year's Nobel Prize in chemistry for their studies of ubiquitin-mediated protein degradation, the Royal Swedish Academy of Sciences announced last week. At the beginning of the 1980s, they discovered how cells degrade proteins in a regulated way. Ciechanover, 57, and Hershko, 67, are both professors at the Technion-Israel Institute of Technology in Haifa, Israel. Ciechanover received his medical degree from the same institution. Hershko holds a medical degree from the Hadassah Medical School of the Hebrew University in Jerusalem. Rose, 78, is a specialist at the Universityof California, Irvine. He holds a doctorate from the Universityof Chicago. The three laureates will equally share the SEK 10 million ($1.4 million) prize.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.